% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Maida:141826,
author = {A. Maida$^*$ and A. Zota$^*$ and A. Vegiopoulos$^*$ and S.
Appak-Baskoy$^*$ and H. Augustin$^*$ and M. Heikenwalder$^*$
and S. Herzig$^*$ and A. J. Rose$^*$},
title = {{D}ietary protein dilution limits dyslipidemia in obesity
through {FGF}21-driven fatty acid clearance.},
journal = {The journal of nutritional biochemistry},
volume = {57},
issn = {0955-2863},
address = {New York, NY [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2018-02094},
pages = {189 - 196},
year = {2018},
abstract = {Recent studies have demonstrated that dietary protein
dilution (PD) can promote metabolic inefficiency and improve
glucose metabolism. However, whether PD can promote other
aspects of metabolic health, such as improve systemic lipid
metabolism, and mechanisms therein remains unknown. Mouse
models of obesity, such as high-fat-diet-fed C57Bl/6 N mice,
and New Zealand Obese mice were fed normal (i.e., $20\%P)$
and protein-dilute (i.e., $5\%EP)$ diets. FGF21-/- and
Cd36-/- and corresponding littermate +/+ controls were also
studied to examine gene-diet interactions. Here, we show
that chronic PD retards the development of
hypertrigylceridemia and fatty liver in obesity and that
this relies on the induction of the hepatokine fibroblast
growth factor 21 (FGF21). Furthermore, PD greatly enhances
systemic lipid homeostasis, the mechanisms by which include
FGF21-stimulated, and cluster of differentiation 36 (CD36)
mediated, fatty acid clearance by oxidative tissues, such as
heart and brown adipose tissue. Taken together, our
preclinical studies demonstrate a novel nutritional
strategy, as well as highlight a role for FGF21-stimulated
systemic lipid metabolism, in combating obesity-related
dyslipidemia.},
cin = {A170 / A171 / A190 / F180},
ddc = {640},
cid = {I:(DE-He78)A170-20160331 / I:(DE-He78)A171-20160331 /
I:(DE-He78)A190-20160331 / I:(DE-He78)F180-20160331},
pnm = {323 - Metabolic Dysfunction as Risk Factor (POF3-323)},
pid = {G:(DE-HGF)POF3-323},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29751292},
doi = {10.1016/j.jnutbio.2018.03.027},
url = {https://inrepo02.dkfz.de/record/141826},
}